Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · TransMedics Group (TMDX)

TransMedics full-year 2024 revenue rises 83% to $441.5 million; net income $35.5 million

Positive Impact 3 of 5 earnings Written later

TransMedics reported fourth-quarter and full-year 2024 results on February 27, 2025, with revenue of $121.6 million for the quarter, up 50%, and $441.5 million for the year, up 83%. The company posted full-year net income of $35.5 million, or $1.01 per diluted share, compared with a net loss of $25.0 million in 2023, and expects 2025 revenue of $530 million to $552 million.

Key points

  • Q4 2024 revenue of $121.6 million, up 50% from $81.2 million; Q4 net income of $6.9 million, or $0.19 per diluted share
  • Full-year 2024 gross margin of 59.4%, down from 63.8% in 2023; operating expenses of $224.6 million
  • 2025 revenue outlook of $530 million to $552 million, representing 20% to 25% growth
  • Cash of $336.7 million as of December 31, 2024

The filing

CompanyTransMedics Group (TMDX)
Form8-K, current report
Filed with the SECFeb 27, 2025, 4:15 PM ET
Accession number0000950170-25-029071

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 27, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.